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Abstract
Objective: This study was undertaken to assess the current manage
ment and outcome of patients with stage I adenocarcinoma of the
endometrium.
Methods: One hundred thirty-five patients with stage I adenocarci
noma of the endometrium were treated with hysterectomy, bilateral
salpingooopherectomy, and surgical staging. Patients were then
stratified into high risk or low risk groups based on grade, depth of
myometrial invasion, and the presence or absence of lymphvascular
space invasion. Postoperative treatment was then individualized
based on risk assessment.
Results: Sixteen of 135 patients (12%) underwent postoperative
adjuvant pelvic radiation. The remaining patients were treated with
observation following surgery. Actuarial survival at three years was
97%.
Conclusions: Surgical staging of endometrial cancer provides criti
cal information with regard to the extent of cancer and prognosis.
When cancer is confined to the uterine corpus, histopathologic
findings can be used to assess individual patient risk; high risk
patients may then be selected for postoperative radiation. Relatively
few patients will require adjuvant treatment and overall survival
appears excellent.
Introduction
The primary treatment for adenocarcinoma of the endometrium
generally involves total hysterectomy and bilateral
salpingooopherectomy. In 1988 the International Federation of
Gynecology and Obstetrics (FIGO) modified the staging of en
dometrial cancer from a clinical to a surgical staging system. This
clearly provides a better assessment of the extent of disease; this
knowledge then allows for more individualized therapy. Patients
with extrauterine disease or with identifiable risk factors may then
be selected for postoperative radiation or more aggressive therapy.
Unnecessary treatment may be avoided in the low risk patient.
Frequently, however, women with endometrial cancer undergo
hysterectomy and salpingooopherectomy without the benefit of
regional lymphadenectomy and surgical staging. Perioperative ra
diotherapy is then administered at the discretion of the individual
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physician. Treatment approaches, therefore, may vary consider
ably, depending upon personal experience and anecdotal evidence.
Utilization of adjuvant treatment may be inconsistent and result in
overtreatment or undertreatment of individual patients.
The present study, therefore, was undertaken to review a series of
consecutive patients with FIGO stage I adenocarcinoma of the
endometrium. Patients in this series were surgically staged, then
stratified into high risk and low risk groups based on histopathologic
findings. Postoperative radiotherapy was then administered based
on risk category. This study reports on the results of treatment.
Materials and Methods
Patients with stage I adenocarcinoma of the endometrium were
identifed through The Queen’s Medical Center tumor registry. All
patients treated by the author from July 1989 through December
1995 were identified. Patient information and pathologic findings
were abstracted from patient records. 135 consecutive patients with
surgical-pathologic stage I carcinoma were identified and included
in the study.
All patients underwent hysterectomy and bilateral salpingo
oopherectomy, including two patients who underwent radical hys
terectomy and ten who underwent laparoscopic vaginal hysterec
tomy. 101 patients underwent selective pelvic lymphadenectomy
and 14 patients underwent selective paraaortic lymphadenectomy.
There were 30 patients that had grade 1 or 2 tumors grossly confined
to the endometrium at the time of surgery that did not undergo
staging lymphadenectomy. In addition there were 4 patients that did
not undergo staging lymphadenectomy because of various medical
or technical contraindications. No patients received preoperative
radiation; all patients with disease documented beyond the uterine
corpus were excluded from this series.
There were 124 patients with endometrioid adenocarcinoma and
11 with papillary serous or clear cell histology. Lymph-vascular
space invasion was found in 16 patients. Table 1 summarizes
findings regarding substage and grade.
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Table 1 .— Tumor grade stratified by substage.
Substage
Grade IA lB IC Total
1 42 17 1 60
2 16 22 8 46
3 6 13 10 29
Total 64 52 19 135
Patients were stratified into high risk and low risk groups based on
the presence of three factors: (1) grade 3 tumor, (2) stage IC (greater
than 50% myometrial invasion), and (3) the presence of lymph-
vascular space invasion. Papillary and clear cell carcinoma were
included in the grade 3 category. Patients with 0 or 1 risk factor
present were considered low risk; patients with 2 or 3 risk factors
present were considered high risk. Life table analysis was used to
calculate survival and chi-square was used as a test of statistical
significance. Postoperative radiotherapy was administered accord
ing to histopathologic findings and risk category. Radiotherapy
consisted of external radiotherapy (45Gy) to the whole pelvis
followed by a single intracavitary application of vaginal colpostats.
Results
There were 15 patients in the high risk category and 120 patients
in the low risk category. Sixteen of 135 patients (12%) received
postoperative radiation. All patients in the high risk group were
referred for radiation; three patients in this group declined treatment.
Four patients in the low risk group did not undergo staging lym
phadenectomy and were treated with radiation; two patients with
stage TB papillary serous carcinoma, and two patients with stage lB
grade 3 adenocarcinoma. Actuarial survival for the entire group at
three years was 97%. Survival for the low risk group was 98%, and
85% for the high risk group at three years. The difference in survival
between the low risk and high risk groups was statistically signifi
cant (p < .05).
Ten patients developed recurrent disease. Two patients in the high
risk group (13%) developed distant metastases and died of their
disease. Seven patients in the low risk group (5.8%) developed local
(ie. vaginal) recurrences. These were all treated with radiation. Four
of these patients remain free of disease; one has been lost to follow-
up; two have died of their cancer. Both patients that died of local
recurrence had persistent local disease following radiation. There
was one distant failure in the low risk group; this patient had one risk
factor present (high grade). The two high risk patients with distant
metastases presented with all three risk factors present. Of the seven
with local recurrences, six had no risk factors present; one had stage
lB clear cell carcinoma. Although all local recurrences occurred in
the low risk group, this was not statistically significant (p> .05). The
incidence of distant metastases, however, was significantly higher
in the high risk group (p < .05).
In this series there were 28 patients with one risk factor present.
Four did not undergo staging lymphadenectomy because of medical
or technical reasons; these four were treated with postoperative
radiation. The remaining 24 were surgically staged and treated with
observation alone following hysterectomy. Of these 24 patients
there was one local recurrence (4%) and one distant recurrence
(4%).
Discussion
Carey et al.’, in 1995 reported on a series of 384 patients with
clinical stage I adenocarcinoma of the endometrium. In this series
low risk patients were defined as grade 1 or 2 with less than 50%
myometrial invasion. Adjuvant radiotherapy was not utilized for
low risk patients and five year survival was 95%. Patients with deep
myometrial invasion or high grade tumors were generally treated
with postoperative radiation. Forty-one percent of patients received
adjuvant radiation; survival at three years for the high risk group was
81% and overall survival for the entire series was 92%. In the present
series 12% of patients received radiation and overall survival at
three years was 97%. This series utilizes surgical staging and
therefore a different classification scheme. The presence of high
grade, deep myometrial invasion, and/or lymph-vascular space
invasion were used to stratify patients: patients with Oor 1 risk factor
present were low risk, and patients with 2 or 3 risk factors were high
risk. This scheme assigns select ‘high’ risk patients with negative
lymph nodes into the low risk category: stage IC grade 1,2 cancer,
stage IA or B grade 3 cancer, and patients with stage lB grade 1 or
2 cancer with lymph-vascular space invasion. With surgical staging
and negative regional nodes, the recurrence risk in this group
appears low. There were 24 of these patients who did not receive
postoperative radiation; there was one local recurrence and one
distant recurrence. Of the 91 patients with no risk factors present
there were six local recurrences (5%) and no distant recurrences.
Three year survival for entire low risk group was 98%.
Kadar et. al.2 reported similar findings in 262 patients who were
similarly stratified by grade, depth of myometrial invasion, lymph-
vascular invasion, and cervical stromal invasion. Of 220 patients
with 0 or I risk factor present, 27% underwent postoperative
radiation and 5 year survival was 97%.
There is some question as to whether low risk patients benefit
from postoperative vaginal brachytherapy to prevent local recur
rence. Piver et. al.3 reported no local recurrences in 90 low risk
women treated with hysterectomy and postoperative vaginal
brachytherapy. Kucera4 reported a local recurrence rate of 0.8% in
a similarly treated group. In Carey’s series the incidence of local
recurrence in low risk patients treated with surgery alone was 2.6%
with an associated mortality of 1.3%. Elliott et. a15 reported a 4.9%
incidence of local recurrence in low risk patients treated with
surgery alone. The incidence of local recurrence in the present series
is similar (5.8%); with a mortality of 1.6%. It would appear,
therefore, that postoperative vaginal brachytherapy in all low risk
patients may reduce the risk of a fatal local recurrence by 1-2%. It
is difficult to assess whether this represents a meaningful decrease
in mortality. Certainly any major complications resulting from the
routine use of brachytherapy would obviate any marginal improve
ment in survival.
Ackerman et. al •6 reviewed 54 patients with recurrent endometrial
cancer. Eleven of 14 patients (79%) with vaginal vault recurrences
confined to the vaginal mucosa were controlled with pelvic radiation
at the time of relapse. Therefore in low risk patients, withholding
radiation until the time of relapse appears to be a reasonable option.
It bears emphasis, however, that as vaginal vault recurrences are not
uncommon and have a reasonable likelihood of salvage, these
patients should be monitored quite closely in the postoperative
period.
The postoperative management ofhigh risk patients remains more
problematic. Postoperative pelvic radiation appears to result in
excellent local control, however these patients remain at significant
risk for systemic failure. A number of studies7’89 have failed to
demonstrate a survival benefit for high risk patients undergoing
postoperative pelvic radiation. Pelvic radiation may simply alter the
pattern of recurrence rather than significantly impacting survival.
There is an ongoing trial sponsored by the Gynecologic Oncology
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Group randomizing high risk Stage I patients to postoperative
radiation versus systemic chemotherapy. The results of this trial
should yield valuable information regarding the adjuvant treatment
of high risk patients.
In summary, the surgical staging of endometrial cancer provides
vital information with regard to the extent of cancer and ultimate
prognosis. When cancer is confined to the uterine corpus histopatho
logic findings can be used to stratify patients into high risk and low
risk groups. Postoperative therapy can then be tailored to the
individual patient.
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